{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:00:26Z","timestamp":1792670426499,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jdermsci.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T12:40:48Z","timestamp":1673268048000},"page":"12-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study"],"prefix":"10.1016","volume":"109","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Alexis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Muscianisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Kianifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Steadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra Prasad","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Garcet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdermsci.2023.01.003_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol. Ther. (Heidelb.)"},{"issue":"3","key":"10.1016\/j.jdermsci.2023.01.003_bib2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.jdermsci.2023.01.003_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jdermsci.2023.01.003_bib4","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jdermsci.2023.01.003_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090284","article-title":"IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model","volume":"9","author":"Chiricozzi","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jdermsci.2023.01.003_bib6","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.jdermsci.2023.01.003_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107925","article-title":"Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: physical and pharmacological properties underlie the observed clinical efficacy and safety","volume":"229","author":"Kolbinger","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.jdermsci.2023.01.003_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jdermsci.2023.01.003_bib9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.jdermsci.2023.01.003_bib10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.jdermsci.2023.01.003_bib11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Thaci","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2023.01.003_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.jdermsci.2023.01.003_bib13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-018-0265-y","article-title":"Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-Week CLARITY results)","volume":"8","author":"Bagel","year":"2018","journal-title":"Dermatol. Ther."},{"issue":"1","key":"10.1016\/j.jdermsci.2023.01.003_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdv.16558","article-title":"Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)","volume":"35","author":"Bagel","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2023.01.003_bib15","unstructured":"R. Langley, B. Sigugeirsson, J. Szepietowski, T.F. Tsai, A. de Vera, P. Charef, et al., Secukinumab maintains improvements in psoriasis through five years of treatment: a randomized extension of the phase III ERASURE and FIXTURE trials, AAD Annual Meeting, March 1\u20135, 2019; Washington, DC. Abstract 10052."},{"issue":"9","key":"10.1016\/j.jdermsci.2023.01.003_bib16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.jdermsci.2023.01.003_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40265-021-01476-3","article-title":"Secukinumab: a review in psoriatic arthritis","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jdermsci.2023.01.003_bib18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","article-title":"Secukinumab: a review in ankylosing spondylitis","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jdermsci.2023.01.003_bib19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2133.1995.tb02696.x","article-title":"Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro","volume":"133","author":"Leigh","year":"1995","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.jdermsci.2023.01.003_bib20","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaci.2019.10.041","article-title":"Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis","volume":"145","author":"Tomalin","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.jdermsci.2023.01.003_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/pst.477","article-title":"A guide to the design and analysis of small clinical studies","volume":"10","author":"Kianifard","year":"2011","journal-title":"Pharm. Stat."},{"issue":"4","key":"10.1016\/j.jdermsci.2023.01.003_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jama.2015.19394","article-title":"Analyzing repeated measurements using mixed models","volume":"315","author":"Detry","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jdermsci.2023.01.003_bib23","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.jaci.2019.01.017","article-title":"Modulation of inflammatory gene transcripts in psoriasis vulgaris: differences between ustekinumab and etanercept","volume":"143","author":"Brodmerkel","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jdermsci.2023.01.003_bib24","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.jdermsci.2023.01.003_bib25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/exd.14117","article-title":"The miR-155\/GATA3\/IL37 axis modulates the production of proinflammatory cytokines upon TNF-\u03b1 stimulation to affect psoriasis development","volume":"29","author":"Wang","year":"2020","journal-title":"Exp. Dermatol."},{"issue":"4","key":"10.1016\/j.jdermsci.2023.01.003_bib26","article-title":"MiR-150 regulates human keratinocyte proliferation in hypoxic conditions through targeting HIF-1\u03b1 and VEGFA: implications for psoriasis treatment","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jdermsci.2023.01.003_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/JID.2015.409","article-title":"MicroRNAs in psoriasis","volume":"136","author":"Hawkes","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"23","key":"10.1016\/j.jdermsci.2023.01.003_bib28","first-page":"9228","article-title":"MiR-155 contributes to normal keratinocyte differentiation and is upregulated in the epidermis of psoriatic skin lesions","volume":"21","author":"Beer","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.jdermsci.2023.01.003_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.0303-6987.2004.0220.x","article-title":"K16 expression in uninvolved psoriatic skin: a possible marker of pre-clinical psoriasis","volume":"31","author":"Bhawan","year":"2004","journal-title":"J. Cutan. Pathol."},{"issue":"9","key":"10.1016\/j.jdermsci.2023.01.003_bib30","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/jid.2009.67","article-title":"Expression of the vanin gene family in normal and inflamed human skin: induction by proinflammatory cytokines","volume":"129","author":"Jansen","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.003_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/964069","article-title":"IL-6 as a druggable target in psoriasis: focus on pustular variants","volume":"2014","author":"Saggini","year":"2014","journal-title":"J. Immunol. Res."},{"issue":"3","key":"10.1016\/j.jdermsci.2023.01.003_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.01.003_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.jdermsci.2023.01.003_bib34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ced.12323","article-title":"Genetic markers of treatment response to tumour necrosis factor-\u03b1 inhibitors in the treatment of psoriasis","volume":"39","author":"Ryan","year":"2014","journal-title":"Clin. Exp. Dermatol."},{"issue":"9","key":"10.1016\/j.jdermsci.2023.01.003_bib35","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","article-title":"Obesity and psoriasis: body weight and body mass index influence the response to biological treatment","volume":"25","author":"Puig","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"Suppl 1","key":"10.1016\/j.jdermsci.2023.01.003_bib36","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1529-8019.2009.01281.x","article-title":"Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy","volume":"23","author":"Bardazzi","year":"2010","journal-title":"Dermatol. Ther."},{"issue":"6","key":"10.1016\/j.jdermsci.2023.01.003_bib37","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjd.20971","article-title":"Secukinumab dosing every two weeks demonstrated superior efficacy compared with dosing every four weeks in patients with psoriasis weighing 90 kg or more: results of a randomised controlled trial","volume":"186","author":"Augustin","year":"2022","journal-title":"Br. J. Dermatol."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181123000038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181123000038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:52:39Z","timestamp":1760331159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181123000038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0923181123000038"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2023.01.003","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}